A drug used to treat type 2 diabetes may also be used to treat prostate cancer. The corresponding study was published in Molecular Cancer. "This is a significant discovery. For the first time, we have ...

A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer. This is shown by an international study in which researchers at Umeå University, Sweden, have ...

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with ...

TUPELO — Some avid watchers of football broadcasts have no doubt become aware of a drug called Pluvicto. That’s because commercials touting the relatively new drug were meant to target a large ...

The researchers enrolled 92 men with recurring prostate cancer into the trial. Half received radiation alone, while the other ...

For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

* A type 2 diabetes drug, pioglitazone, may reduce the risk of prostate cancer relapse by targeting the PPAR (and) #947; protein * Prostate cancer patients with diabetes on PPAR (and) #947; drugs had ...

Diabetes medications known as GLP-1 receptor agonists (GLP-1RAs), widely prescribed for type 2 diabetes and weight loss, have complex and varied effects on cancer risk that depend on cancer type and ...

MILAN, Italy — In patients with prostate cancer and cardiovascular disease, degarelix (Firmagon, Ferring Pharmaceuticals) is associated with fewer serious adverse events and less all-cause death ...

GLP-1 receptor agonists (RAs) were associated with a 17% lower overall cancer risk in adults with obesity or overweight, with particularly reduced risks for endometrial, ovarian, and meningioma ...